Skip to main content

Featured

Wall Street Pauses as Tech Weakness Weighs on Futures

  U.S. stock futures were mixed as investors navigated lingering volatility following a sharp pullback in major technology names. Dow Jones futures showed a slight uptick, while S&P 500 futures hovered near flat. Nasdaq futures, however, continued to drift lower, reflecting ongoing pressure in the tech sector. The recent downturn in high‑growth technology stocks has prompted a broader shift in market sentiment, with traders rotating toward more defensive positions. Concerns about the sustainability of tech valuations and the impact of AI‑driven competition have added to the cautious mood. Attention now turns to Alphabet’s upcoming earnings report, which is expected to play a pivotal role in shaping the market’s next move. With investors eager for clarity on the company’s AI strategy and advertising performance, the results could either steady the tech landscape or deepen the current uncertainty.
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment